Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
As of midnight last night, Pfizer completed the acquisition of Medivation and therefore enzalutamide (Xtandi) is now being sold in the USA by Pfizer and Astellas and by Astellas in the rest of the world. For the details, see here.
Filed under: Uncategorized | Tagged: enzalutamide, Medivation, Pfizer, Xtandi | Leave a comment »
Despite his last blog post saying that he thought he was “done”, Bill’s still giving to us all from his wisdom and experience. He, and we, hope it will be helpful to all those battling late stage prostate cancer. Click here for earlier parts if you missed them. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cyclophosphamide, Cytoxan, Manning | 4 Comments »
Rumor reaches us that another new biotech company, called Fortis Therapeutics, is to be focused (at least initially) on possible new forms of treatment for late stage prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, Fortis | Leave a comment »
As we have noted more than once before, a major problem with being managed on active surveillance is (potentially) whether one’s clinical management team really has been trained to conduct active surveillance in a sufficiently active manner. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active, quality, standards, surveillance | 5 Comments »
Earlier this year, in late May and early June, Prostate Cancer International (PCaI) conducted what we have described as a very primitive pilot survey on prostate cancer patients’ perceptions of “value” in the management of this disease. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: Diagnosis, Management, patient, results, survey, Treatment, value | 5 Comments »
As we have pointed out regularly over the years, all prostate cancers are by no means the same. And a recently published paper in European Urology makes the inherent diversity in the subtypes of prostate cancer even clearer — even within any one specific patient. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, genetic, genomic, prognosis, result, test, variation | 14 Comments »
When your sitemaster speaks to the assembled audience at the annual meeting of ASTRO this coming Sunday, one point he intends to make relates to the importance and value of clear, straightforward, high-quality communication between physicians and patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: communication, value | 2 Comments »
